Safety profile of remifentanil: A post-marketing study in Indonesia
Remifentanil is a novel short-acting μ-opioid receptor agonist. Hence, it can be used as an alternative to fentanyl with additional short-acting potential. However, the safety profile of remifentanil in the Indonesian population through post-marketing surveillance has not been evaluated yet. Therefo...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Science Publishers LLP
2022
|
| Subjects: | |
| Online Access: | https://repository.ugm.ac.id/283444/1/Jarir%20At%20Thobari_Safety%20profile%20of%20remifentanil.pdf |
| _version_ | 1826050646272376832 |
|---|---|
| author | Thobari, Jarir At Haposan, Jonathan Hasian Chandra, Lukman Ade Hidayati, Nastia Dewi, Rianiasa Karunia Purnamasari, Rita Wahyu Pudjiati, Dyah Juliana |
| author_facet | Thobari, Jarir At Haposan, Jonathan Hasian Chandra, Lukman Ade Hidayati, Nastia Dewi, Rianiasa Karunia Purnamasari, Rita Wahyu Pudjiati, Dyah Juliana |
| author_sort | Thobari, Jarir At |
| collection | UGM |
| description | Remifentanil is a novel short-acting μ-opioid receptor agonist. Hence, it can be used as an alternative to fentanyl with additional short-acting potential. However, the safety profile of remifentanil in the Indonesian population through post-marketing surveillance has not been evaluated yet. Therefore, this study aims to evaluate the safety profiles of remifentanil in a multicenter pharmacovigilance study in Indonesia. There were 42 patients who used remifentanil during the 3 months of observation in six referral hospitals in Indonesia. It was found that 35 patients (83%) experienced at least one adverse event. There were 54 adverse events recorded during the observations, with hypotension and bradycardia being the most common adverse events, followed by nausea, respiratory depression, dizziness, shivering, warm sensation, and muscle rigidity. Based on the previous safety data, most of these adverse events were recognized as common adverse drug reactions of remifentanil. The expert panel meeting concluded that, from those adverse events, 98% were possibly related to remifentanil and only one adverse event was unlikely related. Based on this pharmacovigilance study, there are no additional safety concerns related to remifentanil as an analgesic and sedative drug indicated for patients on intubation, invasive mechanical ventilation, and noninvasive ventilation. |
| first_indexed | 2024-03-14T00:07:52Z |
| format | Article |
| id | oai:generic.eprints.org:283444 |
| institution | Universiti Gadjah Mada |
| language | English |
| last_indexed | 2024-03-14T00:07:52Z |
| publishDate | 2022 |
| publisher | Open Science Publishers LLP |
| record_format | dspace |
| spelling | oai:generic.eprints.org:2834442023-11-21T04:00:56Z https://repository.ugm.ac.id/283444/ Safety profile of remifentanil: A post-marketing study in Indonesia Thobari, Jarir At Haposan, Jonathan Hasian Chandra, Lukman Ade Hidayati, Nastia Dewi, Rianiasa Karunia Purnamasari, Rita Wahyu Pudjiati, Dyah Juliana Pharmacology and Pharmaceutical Sciences Remifentanil is a novel short-acting μ-opioid receptor agonist. Hence, it can be used as an alternative to fentanyl with additional short-acting potential. However, the safety profile of remifentanil in the Indonesian population through post-marketing surveillance has not been evaluated yet. Therefore, this study aims to evaluate the safety profiles of remifentanil in a multicenter pharmacovigilance study in Indonesia. There were 42 patients who used remifentanil during the 3 months of observation in six referral hospitals in Indonesia. It was found that 35 patients (83%) experienced at least one adverse event. There were 54 adverse events recorded during the observations, with hypotension and bradycardia being the most common adverse events, followed by nausea, respiratory depression, dizziness, shivering, warm sensation, and muscle rigidity. Based on the previous safety data, most of these adverse events were recognized as common adverse drug reactions of remifentanil. The expert panel meeting concluded that, from those adverse events, 98% were possibly related to remifentanil and only one adverse event was unlikely related. Based on this pharmacovigilance study, there are no additional safety concerns related to remifentanil as an analgesic and sedative drug indicated for patients on intubation, invasive mechanical ventilation, and noninvasive ventilation. Open Science Publishers LLP 2022-05 Article PeerReviewed application/pdf en https://repository.ugm.ac.id/283444/1/Jarir%20At%20Thobari_Safety%20profile%20of%20remifentanil.pdf Thobari, Jarir At and Haposan, Jonathan Hasian and Chandra, Lukman Ade and Hidayati, Nastia and Dewi, Rianiasa Karunia and Purnamasari, Rita Wahyu and Pudjiati, Dyah Juliana (2022) Safety profile of remifentanil: A post-marketing study in Indonesia. Journal of Applied Pharmaceutical Science, 12 (5). pp. 165-170. ISSN 2231-3354 https://japsonline.com/abstract.php?article_id=3645&sts=2 10.7324/JAPS.2022.120514 |
| spellingShingle | Pharmacology and Pharmaceutical Sciences Thobari, Jarir At Haposan, Jonathan Hasian Chandra, Lukman Ade Hidayati, Nastia Dewi, Rianiasa Karunia Purnamasari, Rita Wahyu Pudjiati, Dyah Juliana Safety profile of remifentanil: A post-marketing study in Indonesia |
| title | Safety profile of remifentanil: A post-marketing study in Indonesia |
| title_full | Safety profile of remifentanil: A post-marketing study in Indonesia |
| title_fullStr | Safety profile of remifentanil: A post-marketing study in Indonesia |
| title_full_unstemmed | Safety profile of remifentanil: A post-marketing study in Indonesia |
| title_short | Safety profile of remifentanil: A post-marketing study in Indonesia |
| title_sort | safety profile of remifentanil a post marketing study in indonesia |
| topic | Pharmacology and Pharmaceutical Sciences |
| url | https://repository.ugm.ac.id/283444/1/Jarir%20At%20Thobari_Safety%20profile%20of%20remifentanil.pdf |
| work_keys_str_mv | AT thobarijarirat safetyprofileofremifentanilapostmarketingstudyinindonesia AT haposanjonathanhasian safetyprofileofremifentanilapostmarketingstudyinindonesia AT chandralukmanade safetyprofileofremifentanilapostmarketingstudyinindonesia AT hidayatinastia safetyprofileofremifentanilapostmarketingstudyinindonesia AT dewirianiasakarunia safetyprofileofremifentanilapostmarketingstudyinindonesia AT purnamasariritawahyu safetyprofileofremifentanilapostmarketingstudyinindonesia AT pudjiatidyahjuliana safetyprofileofremifentanilapostmarketingstudyinindonesia |